(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...

Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain ...

The severe asthma market is fueled by the rising prevalence of the condition, particularly in urban areas, alongside the emergence of innovative therapies ...

Revenue: US$2.47b (down 2.5% from 3Q 2023). Net income: US$388.5m (up from US$68.1m loss in 3Q 2023). Profit margin: 16% (up from net loss in 3Q 2023). The move to profitability was driven by lower ...

Free TV coverage of the Tour de France could continue in the UK after Warner Bros. Discovery landed the exclusive UK rights to the event – having been the only bidder for them. WBD, which owns ...

On Thursday, TD Cowen reaffirmed its confidence in Biogen (NASDAQ:BIIB) shares, maintaining a Buy rating but lowering the price target to $275 from the previous $300. The adjustment follows Biogen's ...

fans aren’t shy about speculating about the new logo. If you’ve got a celebrity story, video or pictures get in touch with the Metro.co.uk entertainment team by emailing us [email protected] ...

Investing.com -- Biogen (NASDAQ:BIIB) shares slid around 3% Thursday after Morgan Stanley analysts downgraded the stock from Overweight to Equal Weight and slashed the price target from $285 to $204.

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...